Ignite Creation Date:
2024-05-05 @ 5:36 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00492752
Status:
COMPLETED
Last Update Posted:
2014-04-16
First Post:
2007-06-26
Brief Title:
A Randomized Double-Blinded Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Randomized Double-blinded Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Status:
COMPLETED
Status Verified Date:
2014-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is
Find out if patients receiving Sorafenib will live longer
Find out if Sorafenib has any effect on patient reported outcomes
Find out if Sorafenib prevents the growth or shrinks liver tumors and or their metastases
Determine the pharmacokinetics PK in patients with liver cancer
Find out if patients receiving Sorafenib will live longer
Find out if Sorafenib has any effect on patient reported outcomes
Find out if Sorafenib prevents the growth or shrinks liver tumors and or their metastases
Determine the pharmacokinetics PK in patients with liver cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None